Dr. Ho has more than 30 years of experience in the healthcare and finance industries. She serves on the board of directors for Agios Pharmaceuticals, BioMarin Pharmaceutical, Kyntra Bio, Neumora Therapeutics, Parexel, the Aaron Diamond AIDS Research Center, and the Institute for Protein Innovation. Dr. Ho is also a venture partner at Aulis Capital and a member of the Biotech Advisory Panel of the Stock Exchange of Hong Kong. Previously, she was a board member of GRAIL and a venture partner of Qiming Venture Partners. She is a retired partner of the Goldman Sachs Group where she served as senior biotechnology analyst, co-head of healthcare for global investment research and advisory director for healthcare investment banking. Prior to Goldman Sachs, Dr. Ho held various managerial positions in strategic planning, marketing and research at DuPont Merck Pharmaceuticals and DuPont de Nemours & Company. She was a postdoctoral fellow at Harvard Medical School and a graduate of the Advanced Management Program at The Fuqua School of Business, Duke University. Dr. Ho received a Ph.D. in Microbiology and Immunology and a B.S. from the State University of New York, Downstate Medical Center.
